Scroll for more





Peter Greenleaf
Chairman and Chief Executive Officer

Woody Bryan, Ph.D.
Senior Vice President, Business Development and Licensing


Elissa Cote
Senior Vice President, Global Strategic Marketing
and Alliance Management

Max Donley
Executive Vice President, Global Human Resources,
IT and Strategy

Alex Driggs
General Counsel, Corporate Secretary

Peter Kiener, D. Phil
Chief Scientific Officer

Peter Lichtlen, M.D., Ph.D.
Chief Medical Officer

Jason Meyenburg
Chief Commercial Officer


Peter Pfreundschuh
Chief Financial Officer

Silvia Taylor
Senior Vice President, Investor
Relations and Corporate Affairs

Contact Us
Tel: +1-301-961-3400

Sucampo Pharmaceuticals, Inc. is focused on the development and commercialization of specialized medicines that meet major unmet medical needs of patients worldwide. Sucampo has two marketed products – AMITIZA, its lead product, and RESCULA – and a late-stage pipeline of product candidates in clinical development for orphan disease areas. VTS-270 is a mixture of 2-hydroxypropyl-B-cyclodextrins with a specific compositional fingerprint that has been granted orphan designation in the U.S. and Europe and is in a pivotal Phase 2/3 clinical trial for the treatment of Niemann-Pick Disease Type C-1. Sucampo has an option for the North American rights to CPP1- x/sulindac, which is in Phase 3 development for the treatment of familial adenomatous polyposis and has been granted orphan drug designation in the U.S. A global company, Sucampo is headquartered in Rockville, Maryland, and has operations in Japan and Switzerland.